Evidence behind this recommendation.
Selected studies from our library that inform the recommendations on this page. Evidence grade shown when available.
Acupuncture for the treatment of pruritus: peripheral and central mechanisms
“Detailed review of the antipruritic mechanisms of acupuncture: modulation of IL-31, substance P, and CGRP in unmyelinated C fibers, with documented reduction of pruritus in chronic dermatologic conditions.”
Skin-brain axis: neural pathways in acupuncture treatment
“Neural mechanisms of the skin-brain axis in acupuncture, including modulation of cutaneous neuropeptides, neuroinflammation, and nervous-immune system interaction in the skin.”
What Atopic Dermatitis Is
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease, characterized by intense pruritus, dry skin, erythema, lichenification, and eczematous lesions. It is part of the "atopic march" together with allergic rhinitis and bronchial asthma. AD affects 15%–20% of children and 1%–3% of adults in industrialized countries, with increasing prevalence over recent decades attributed to environmental factors and modern lifestyle.
The impact on quality of life is profound: nocturnal pruritus interrupts sleep, secondary infection by Staphylococcus aureus amplifies flares, and the itch-scratch-inflame cycle perpetuates the disease. Studies show that the disease burden of severe AD is comparable to diabetes and heart failure in terms of functional impairment.
Pathophysiology of Atopic Dermatitis
Skin barrier defect
Mutations in filaggrin (FLG) and desmoglein 1 compromise the epidermal barrier; increased TEWL; penetration of allergens and Staphylococcus aureus
Activation of dendritic cells and ILC2s
TSLP, IL-25, and IL-33 released by damaged epithelium activate ILC2s and dendritic cells; initiation of the Th2 response
Th2 polarization and cytokines
IL-4 and IL-13 suppress filaggrin and ceramides (worsening of the barrier); IL-31 (the main pruritus mediator); elevated IgE
Central sensitization to pruritus
Chronic scratching sensitizes unmyelinated C neurons; substance P and CGRP amplify pruritus; hyperreactive brain-skin axis
Superinfection by S. aureus
S. aureus colonizes 90% of lesions; toxins (enterotoxins B, A) act as superantigens; amplify the Th2 and Th17 response
Severity Assessment
- SCORAD (SCORing Atopic Dermatitis, 0–103): mild <25; moderate 25–50; severe >50
- EASI (Eczema Area and Severity Index): correlation with therapeutic response in clinical trials
- POEM (Patient-Oriented Eczema Measure): patient-reported assessment — 7 weekly questions
- Pruritus NRS (0–10): the most clinically relevant primary outcome for patient quality of life
- Assessment of sleep impact: nighttime interruptions due to pruritus are the main predictor of impaired quality of life
Conventional Treatments
AD treatment is escalated according to severity. The foundation is intensive emollients to restore the skin barrier and topical corticosteroids for flares. For moderate to severe AD, topical immunosuppressants (calcineurin inhibitors) and biologics have revolutionized prognosis.
THERAPEUTIC APPROACHES IN ATOPIC DERMATITIS
| APPROACH | EFFICACY | LIMITATIONS | COMPATIBLE WITH ACUPUNCTURE? |
|---|---|---|---|
| Intensive emollients and moisturizers | Fundamental — base of any treatment; reduces TEWL | Need for daily and consistent use; variable adherence | Yes — acupuncture does not interfere; combined use recommended |
| Topical corticosteroids | High for acute flares; reduces inflammation and pruritus rapidly | Skin atrophy with prolonged use; corticosteroid phobia limits adherence | Yes — acupuncture reduces flare frequency and intensity |
| Calcineurin inhibitors (tacrolimus, pimecrolimus) | High for face and folds; no atrophic effect | Initial burning; restricted use in children under 2 years | Yes — complementary |
| Dupilumab (anti-IL-4Rα) | Very high for moderate-severe AD; SCORAD −50% to −60% | High cost; injection every 2 weeks; conjunctivitis in 10% | Yes — acupuncture as support and stress management |
| Medical acupuncture | Moderate for pruritus and SCORAD in mild-to-moderate AD | More limited effect in severe AD without biologics; requires 8–12 sessions | Integrates the protocol — especially effective for pruritus and sleep |
How Medical Acupuncture Works in Atopic Dermatitis
Medical acupuncture acts on AD through multiple mechanisms: it modulates the Th2 immune response, reduces pruritus mediators (IL-31, substance P, CGRP), stabilizes cutaneous mast cells, and restores the autonomic balance that regulates cutaneous neuroinflammation.
DOCUMENTED IMMUNOMODULATORY EFFECTS
Clinical Studies
Acupuncture for AD is supported by randomized trials and a Cochrane meta-analysis (2020) that identified significant benefits, especially for control of pruritus and sleep quality.
CLINICAL OUTCOMES — ACUPUNCTURE IN MEDICINE 2018 (N=62, 12 WEEKS)
What the Studies Show
- Acupuncture described as superior to control for pruritus and SCORAD in a meta-analysis of RCTs — variable magnitude
- Modulation of serum IL31 described in mechanistic studies as a potential antipruritic pathway
- Improvement in nocturnal sleep is one of the most impactful outcomes for quality of life when observed
- Studies suggest a trend of reduction in topical corticosteroid use — does not replace medical indication
- More consistent response in mild-to-moderate AD; severe AD requires specific dermatologic treatment
Modern Approach: Integrative Acupuncture in Atopic Dermatitis
Medical acupuncture occupies a central role in the management of pruritus, sleep, and stress in the integrative AD protocol — three areas where its impact is immediate and clinically significant.
Integrative Protocol for Atopic Dermatitis
Fundamental base (continuous)
Emollients 2x/day independent of flares; hygiene with hypoallergenic soap; identification and control of triggers (mites, fragrances, synthetic fabrics)
Active phase — acupuncture (weeks 1–8)
Acupuncture 1–2x/week; SP-10+LI-11+BL-40+ST-36+LI-4+SP-6; priority for pruritus control (antipruritic protocol); topical corticosteroid for acute flares
Maintenance (after week 8)
Biweekly or monthly acupuncture; reassessment of SCORAD and POEM; adjustment of topical treatment with the dermatologist; acupuncture for stress if identified as a trigger
Management of psychological triggers
Stress, anxiety, and sleep deprivation are recognized triggers of atopic flares; acupuncture for the autonomic nervous system (HT-7, PC-6, GV-20) complements skin treatment
When to See a Medical Acupuncturist
Medical acupuncture in AD is especially indicated for control of pruritus, improvement of sleep, and reduction of dependence on topical corticosteroids in mild-to-moderate AD.
Profiles With Best Response to Acupuncture
- Mild-to-moderate AD (SCORAD 10–50) with pruritus as the main complaint and impact on sleep
- AD with a stress component identified as a trigger of frequent flares
- Patients with corticosteroid phobia who wish to reduce topical corticosteroid use with safe support
- AD with associated allergic rhinitis and asthma — integrative treatment of the atopic march
- Adults with late-onset AD with a stress component and impaired quality of life
Frequently Asked Questions
Frequently Asked Questions
No — needles must never be inserted into skin with active AD lesions (erythema, vesicles, crusts, erosions) due to the risk of secondary infection, especially in skin colonized by S. aureus. Acupuncture points are selected on intact skin. During extensive flares, acupuncture is maintained at distal points (hands, legs) until the local skin recovers.
Yes — the antipruritic effect is often the most immediate. Many patients report significant reduction in pruritus during the session itself and in the following 24–48 hours. The effect accumulates over sessions, becoming more durable. SP-10 and LI-11 have a documented antipruritic action with onset of effect 15–20 minutes after insertion.
No — emollients are the irreplaceable foundation of AD treatment, since they restore the deficient skin barrier and hydrate chronically dry skin. Acupuncture complements the antiinflammatory and antipruritic effect, but has no direct action on the skin barrier. Both should be used continuously and together.
Improvement in pruritus and sleep generally occurs in the first 2–4 weeks. Visible improvement of the lesions (erythema, lichenification) is slower — expected between 6–12 weeks of regular treatment. The reduction in SCORAD documented in studies (−14.8 pts in 12 weeks) is equivalent to a one-category improvement in severity (e.g., from moderate to mild).
In general, the two approaches can be combined safely, since they act on distinct pathways — dupilumab acts systemically on the IL-4/IL-13 pathway, and acupuncture on complementary mechanisms (neurogenic pruritus, stress, sleep). The combination should be evaluated by the attending dermatologist; additive effects on quality of life may occur, but require confirmation in specific studies.